Yes it is obvious at this point that there is an abundance of competition in the ALZ diagnostic space. Lympro has been "launched" for a quarter now and nothing. Amarantus is far from cornering the market, I can not even say that out loud with a straight face. I believe MSprecise is worth more than Lympro at this point and we paid 11 million for the entire company. That should be a good indicator of what Lympro is worth. If we sold Lympro today for 10 million bucks id be happy to move on with some non dilutive financing to fund Elto 2b.